By Dominic ChoppingSTOCKHOLM--Swedish private-equity firm EQT AB on Monday declared its offer for pharmaceutical development and manufacturing company Recipharm AB unconditional. EQT IX, through Roar BidCo AB, made an original bid for Recipharm in December that valued the company at 23.64 billion Swedish kronor ($2.85 billion), but raised the bid to SEK24.93 billion last month. Together with the shares already held or otherwise controlled by Roar BidCo and its closely related parties, its shareholding in Recipharm amounts to 96 million shares, corresponding to 95.1% of the share capital and 98.3% of the voting rights. Roar BidCo will now initiate compulsory redemption of the remaining shares in Recipharm as well as promote delisting of Recipharm's shares from Nasdaq Stockholm and promote delisting of the convertible bonds from the Frankfurt Stock Exchange, Open Market. Write to Dominic Chopping at dominic.chopping@wsj.com(END) Dow Jones Newswires02-15-21 0458ET

Source: Wall Street Journal February 15, 2021 09:56 UTC